Patient Selection for the Use of Niraparib in Advanced Ovarian Cancer: A Review by Gonzalez A, Kistenfeger Q, Cosgrove CM

Subjects: “…niraparib…”
Get full text

Niraparib perturbs autophagosome-lysosome fusion in pancreatic ductal adenocarcinoma and exhibits anticancer potential against gemcitabine-resistant PDAC by Zehui Yao, Huihui Zhang, Kewei Huang, Guizhong Huang, Pu Xi, Lingmin Jiang, Dailei Qin, Fan Chen, Shengping Li, Ran Wei

Subjects: Get full text

A phase II study evaluating safety and efficacy of niraparib in patients with previously treated homologous recombination defective metastatic esophageal/gastroesophageal junction/... by Ahmed Bilal Khalid, Christos Fountzilas, Heather N. Burney, Hirva Mamdani, Bryan P. Schneider, Christopher Fausel, Susan M. Perkins, Shadia Jalal

Subjects: Get full text

Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer by Whitney S Graybill, Ignace Vergote, Bhavana Pothuri, Maarit Anttila, David M O’Malley, Domenica Lorusso, Ashley F Haggerty, Michel Fabbro, John K Chan, Florian Heitz, Lyndsay J Willmott, Ilan Bruchim, Ying Zhuo, Purificacion Estevez-Garcia, Bradley J Monk, Hannelore Denys, Anja Knudsen, Anna V Tinker, Luis Manso Sanchez, Diane Provencher, Maria Pilar Barretina-Ginesta, John Hartman, Donna V Booth, Antonio Gonzalez-Martin

Subjects:

Niraparib restricts intraperitoneal metastases of ovarian cancer by eliciting CD36-dependent ferroptosis by Ning Jin, Yi-yu Qian, Xiao-fei Jiao, Zhen Wang, Xin Li, Wen Pan, Jin-kai Jiang, Pu Huang, Si-yuan Wang, Ping Jin, Qing-lei Gao, Dan Liu, Yu Xia

Subjects: Get full text